These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 11111188)
1. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Schulman CC; Debruyne FM; Forster G; Selvaggi FP; Zlotta AR; Witjes WP Eur Urol; 2000 Dec; 38(6):706-13. PubMed ID: 11111188 [TBL] [Abstract][Full Text] [Related]
2. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Witjes WP; Schulman CC; Debruyne FM Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Debruyne FM; Witjes WP Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Schulman CC Prostate Suppl; 1994; 5():9-14. PubMed ID: 7513532 [TBL] [Abstract][Full Text] [Related]
5. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Fair WR; Betancourt JE Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380 [TBL] [Abstract][Full Text] [Related]
6. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy. Gao X; Zhou T; Tang YJ; Lu X; Sun YH Asian J Androl; 2009 Jan; 11(1):127-30. PubMed ID: 19050694 [TBL] [Abstract][Full Text] [Related]
8. Effects of androgen deprivation prior to radical prostatectomy in 375 patients. Tunn UW; Acar O; Goldschmidt AJ Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811 [TBL] [Abstract][Full Text] [Related]
9. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740 [TBL] [Abstract][Full Text] [Related]
10. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579 [TBL] [Abstract][Full Text] [Related]
11. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate]. Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse. Kiriyama I; Ogaki K; Ohba S; Nishimura T J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001 [TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776 [TBL] [Abstract][Full Text] [Related]
14. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Lee F; Siders DB; McHug TA; Solomon MH; Klamerus ML Anticancer Res; 1997; 17(3A):1507-10. PubMed ID: 9179187 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S; J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055 [TBL] [Abstract][Full Text] [Related]
17. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269 [TBL] [Abstract][Full Text] [Related]